ELASMOGEN
LIVE

Serial Number

79379490

Owner

Elasmogen Ltd

Attorney

Charlene M. Krogh

Filing Date

Apr 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ELASMOGEN Trademark

Serial Number: 79379490 • Registration: 7567642

ELASMOGEN is a trademark filed by Elasmogen Ltd on April 19, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Elasmogen Ltd (6 trademarks)

Liberty Building,

Entity Type: 99

Trademark Details

Filing Date

April 19, 2023

Registration Date

November 19, 2024

Published for Opposition

September 3, 2024

Goods & Services

Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use

Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services.

Medical services; medical advisory services relating to the treatment, relief and prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; preparation and provision of medical reports to patients and medical professionals; preparation and provision of medical information in the form of reports on pharmaceuticals, advanced therapy medicinal products, and therapeutic antibodies to patients and medical professionals; consultancy, advice and information in the field of healthcare, pharmaceuticals and advanced therapy medicinal products

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 3, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 16, 2025 FICS
FINAL DISPOSITION PROCESSED
Apr 16, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 14, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 27, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 27, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 19, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 19, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 19, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 14, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 31, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 29, 2024 TROA
REFUSAL PROCESSED BY IB
Feb 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 1, 2024 RFCS
REFUSAL PROCESSED BY MPU
Feb 1, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 18, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 17, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 17, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 3, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 28, 2023 REPR